{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:11:52Z","timestamp":1769112712246,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.thromres.2014.02.004","type":"journal-article","created":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T13:03:15Z","timestamp":1392123795000},"page":"886-891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tamoxifen induces resistance to activated protein C"],"prefix":"10.1016","volume":"133","author":[{"given":"Heiko","family":"R\u00fchl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Fimmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shorena","family":"Sukhitashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Welz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walther C.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Rudlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"P\u00f6tzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9472","key":"10.1016\/j.thromres.2014.02.004_bb0005","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.thromres.2014.02.004_bb0010","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jnci\/93.13.979","article-title":"National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1\u20133, 2000","volume":"93","author":"Eifel","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.thromres.2014.02.004_bb0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer \u221296-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.thromres.2014.02.004_bb0020","first-page":"191","article-title":"Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis","volume":"35","author":"Manzoli","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.thromres.2014.02.004_bb0025","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.thromres.2014.02.004_bb0030","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1002\/cncr.24508","article-title":"Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study","volume":"115","author":"Hernandez","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2014.02.004_bb0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1538-7836.2009.03711.x","article-title":"APC resistance: biological basis and acquired influences","volume":"8","author":"Castoldi","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2014.02.004_bb0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives","volume":"97","author":"Rosing","year":"1997","journal-title":"Br J Haematol"},{"issue":"9195","key":"10.1016\/j.thromres.2014.02.004_bb0045","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.thromres.2014.02.004_bb0050","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/j.1538-7836.2004.00983.x","article-title":"Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate","volume":"2","author":"Van Vliet","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.thromres.2014.02.004_bb0055","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2014.02.004_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2004.09.014","article-title":"Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature","volume":"116","author":"Cosman","year":"2005","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.thromres.2014.02.004_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2141.2003.03976.x","article-title":"Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The Breast Cancer Prevention Trial","volume":"120","author":"Cushman","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.thromres.2014.02.004_bb0070","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdh437","article-title":"Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?","volume":"15","author":"Erman","year":"2004","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.thromres.2014.02.004_bb0075","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.fertnstert.2005.06.029","article-title":"Procoagulant state after raloxifene therapy in postmenopausal women","volume":"84","author":"Azevedo","year":"2005","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.thromres.2014.02.004_bb0080","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0038-1650259","article-title":"Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and\/or inherited protein S deficiency","volume":"75","author":"Z\u00f6ller","year":"1996","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.thromres.2014.02.004_bb0085","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1365-2141.1996.d01-1500.x","article-title":"Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation","volume":"92(","author":"Simioni","year":"1996","journal-title":"Br J Haematol"},{"issue":"1\u20132","key":"10.1016\/j.thromres.2014.02.004_bb0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0049-3848(02)00189-5","article-title":"Markers of activated coagulation in patients with factor V Leiden and\/or G20210A prothrombin gene mutation","volume":"107","author":"Gouin-Thibault","year":"2002","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.thromres.2014.02.004_bb0095","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.thromres.2011.11.006","article-title":"The APC-PCI concentration as an early marker of activation of blood coagulation. A study of women on combined oral contraceptives","volume":"130","author":"Bremme","year":"2011","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.thromres.2014.02.004_bb0100","first-page":"1294","article-title":"Allelic discrimination of factor V Leiden using a 5\u2019 nuclease assay","volume":"82","author":"Happich","year":"1999","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2014.02.004_bb0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-0037-1613987","article-title":"Application of the TaqMan-PCR for genotyping of the prothrombin G20210A mutation and of the thermolabile methylenetetrahydrafolate reductase mutation","volume":"84","author":"Happich","year":"2000","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.thromres.2014.02.004_bb0110","first-page":"553","article-title":"Thrombin generation, a function test of the haemostatic-thrombotic system","volume":"96","author":"Hemker","year":"2006","journal-title":"Thromb Haemost"},{"issue":"Suppl. 3","key":"10.1016\/j.thromres.2014.02.004_bb0115","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0049-3848(11)70007-X","article-title":"Thrombin generation tests","volume":"127","author":"Castoldi","year":"2011","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.thromres.2014.02.004_bb0120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1538-7836.2012.04623.x","article-title":"Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay","volume":"10(","author":"M\u00fcller","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.thromres.2014.02.004_bb0125","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.chembiol.2009.03.007","article-title":"An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor","volume":"16","author":"M\u00fcller","year":"2009","journal-title":"Chem Biol"},{"issue":"9","key":"10.1016\/j.thromres.2014.02.004_bb0130","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood.V96.9.3295","article-title":"Hyperprothrombinemia may result in acquired protein C resistance","volume":"96","author":"Tripodi","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2014.02.004_bb0135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1160\/TH05-08-0582","article-title":"Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels","volume":"95","author":"Brugge","year":"2006","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.thromres.2014.02.004_bb0140","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1182\/blood-2003-10-3578","article-title":"Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations","volume":"103","author":"Castoldi","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.thromres.2014.02.004_bb0145","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1001\/archinte.1996.00440150056006","article-title":"Effect of tamoxifen on measurements of hemostasis in healthy women","volume":"156","author":"Mannucci","year":"1996","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.thromres.2014.02.004_bb0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00001721-199910000-00002","article-title":"Influence of factor VIII\/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation","volume":"10","author":"De Mitrio","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.thromres.2014.02.004_bb0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archinte.1992.00400140065015","article-title":"Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy","volume":"152","author":"Love","year":"1992","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.thromres.2014.02.004_bb0160","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bjc.1992.350","article-title":"Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women","volume":"66","author":"Jones","year":"1992","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.thromres.2014.02.004_bb0165","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"Determinants of the APTT- and ETP-based APC sensitivity tests","volume":"3","author":"de Visser","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.thromres.2014.02.004_bb0170","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00001721-199312000-00011","article-title":"The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis","volume":"4(","author":"Pemberton","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2014.02.004_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0959-8049(93)90568-Z","article-title":"Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party","volume":"29A","author":"Cuzick","year":"1992","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2014.02.004_bb0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01811244","article-title":"Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels","volume":"12","author":"Bertelli","year":"1988","journal-title":"Breast Cancer Res Treat"},{"issue":"3\u20134","key":"10.1016\/j.thromres.2014.02.004_bb0185","first-page":"103","article-title":"Diagnosing protein S deficiency: analytical considerations","volume":"49","author":"Persson","year":"2003","journal-title":"Clin Lab"},{"issue":"6","key":"10.1016\/j.thromres.2014.02.004_bb0190","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1160\/TH06-11-0632","article-title":"Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system","volume":"97","author":"Eilertsen","year":"2007","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.thromres.2014.02.004_bb0195","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.thromres.2006.10.013","article-title":"Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis","volume":"120","author":"Eilertsen","year":"2007","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.thromres.2014.02.004_bb0200","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1538-7836.2008.02970.x","article-title":"Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers","volume":"6","author":"Eilertsen","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"13","key":"10.1016\/j.thromres.2014.02.004_bb0205","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnci\/djq211","article-title":"Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer","volume":"102","author":"Garber","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2014.02.004_bb0210","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.breast.2007.07.012","article-title":"Adjuvant therapy and thrombosis: how to avoid the problem?","volume":"16","author":"Levine","year":"2007","journal-title":"Breast"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T08:10:57Z","timestamp":1597479057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0049384814000838"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.02.004","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tamoxifen induces resistance to activated protein C","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}